Treatment of hepatocellular carcinoma in the community: Disparities in standard therapy

Liver Cancer

Volumn 4, Issue 1, 2015, Pages 70-83

  Harlan, Linda C ^a   Parsons, Helen M ^b   Wiggins, Charles L ^c   Stevens, Jennifer L ^d   Patt, Yehuda Z ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c UNIVERSITY OF NEW MEXICO   (United States)

^d INFORMATION MANAGEMENT SERVICES INC   (United States)

Author keywords

Embolization; Insurance; Liver cirrhosis; Liver transplant; Population based

Indexed keywords

INTERFERON; SORAFENIB; SUNITINIB;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CHEMOEMBOLIZATION; COMMUNITY; FEMALE; HEALTH CARE DISPARITY; HEPATITIS B; HEPATITIS C; HISPANIC; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER GRAFT; MAJOR CLINICAL STUDY; MALE; MEDICAID; MORTALITY; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; SYSTEMIC THERAPY;

EID: 84940462764     PISSN: 22351795     EISSN: 16645553     Source Type: Journal    
DOI: 10.1159/000367729     Document Type: Article

References (34)

1. American Cancer Society: Cancer Facts and Figures 2014. Atlanta, GA: American Cancer Society, 2014. Last accessed June 30, 2014 at http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2014/index.
2. El-Serag HB, Mason AC: Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-750.
3. Turati F, Talamini R, Pelucchi C, Polesel J, Franceschi S, Crispo, et al: Metabolic syndrome and hepatocellular carcinoma risk. Br J Cancer. 2013 15;108(1):222-228.
4. Mor E, Tur-Kaspa R, Sheiner P, Schwartz M: Treatment of hepatocellular carcinoma associated with cirrhosis in the era of liver transplantation. Ann Intern Med 1998;129:643-653.
5. Adult primary liver cancer treatment PDQ. National Cancer Institute. Last Accessed May 6, 2014 at http://www.cancer.gov/cancertopics/pdq/treatment/adult-primary-liver/HealthProfessional/page1.
6. NCCN Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers Version 2.2012. National Comprehensive Cancer Center Network 2012. Last accessed March 7, 2012 at http://www.nccn.org/professionals/physician-gls/pdf/hepatobiliary.
7. Alves RC, Alves D, Guz B, Matos C, Viana M, Harriz M, Terrabuio D, Kondo M, Gampel O, Polletti P: Advanced hepatocellular carcinoma. Review of targeted molecular drugs. Ann Hepatol 2011;10:21-27.
8. Rahbari NN, Mehrabi A, Mollberg NM, Mller SA, Koch M, Bchler MW, Weitz J: Hepatocellular carcinoma: current management and perspectives for the future. Ann Surg 2011;253:453-469.
9. Llovet JM: Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 2005;40:225-235.
10. Bruix J, Llovet JM: Major achievements in hepatocellular carcinoma. Lancet 2009;373:614-616.
11. Overview of the SEER Program, National Cancer Institute 2012. Last accessed May 6, 2014 at http://seer. cancer.gov/about/overview.html.
12. Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383.
13. Nathan H, Hyder O, Mayo SC, Hirose K, Wolfgang CL, Choti MA, Pawlik TM: Surgical therapy for early hepatocellular carcinoma in the modern era: a 10-year SEER-Medicare analysis. Ann Surg 2013;258:1022-1027.
14. Bruix J, Sherman M American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-1022.
15. Cauchy F, Soubrane O, Belghiti J: Liver resection for HCC: patients selection and controversial scenarios. Best Pract Res Clin Gastroenterol 2014;28:881-896.
16. Farinati F, Vanin V, Giacomin A, Pozzan C, Cillo U, Vitale A, Di Nolfo AM, Del Poggio P, Benvegnu L, Rapaccini G, Zoli M, Borzio F, Giannini EG, Caturelli E, Trevisani F: The Italian Liver Cancer (ITA.LI.CA) group. BCLC stage B hepatocellular carcinoma and transcatheter arterial chemoembolization: a 20-year survey by the Italian Liver Cancer group. Liver Int 2014; doi:10.1111/liv.12649 [Epub ahead of print].
17. Koniaris LG, Levi DM, Pedroso FE, Franceschi D, Tzakis AG, Santamaria-Barria JA, Tang J, Anderson M, Misra S, Solomon NL, Jin X, DiPasco PJ, Byrne MM, Zimmers TA: Is surgical resection superior to transplantation in the treatment of hepatocellular carcinoma? Ann Surg 2011;254:527-537, discussion 537-538.
18. Canter RJ, Patel SA, Kennedy T, DAngelica MI, Jarnagin WR, Fong Y, Blumgart LH, Freeman RB, DeMatteo RP, Abt PL: Comparative analysis of outcome in patients with hepatocellular carcinoma exceeding the Milan criteria treated with liver transplantation versus partial hepatectomy. Am J Clin Oncol 2011;34:466-471.
19. Llovet JM, Bruix J: Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003;37:429-442.
20. Forner A, Llovet JM, Bruix J: Chemoembolization for intermediate HCC: is there proof of survival benefit? J Hepatol 2012;56:984-986.
21. Wrns MA, Bosslet T, Victor A, Koch S, Hoppe-Lotichius M, Heise M, Hansen T, Pitton MB, Niederle IM, Schuchmann M, Weinmann A, Dber C, Galle PR, Otto G: Prognostic factors and outcomes of patients with hepatocellular carcinoma in non-cirrhotic liver. Scand J Gastroenterol 2012;47:718-728.
22. Sangro B, Bilbao JI, Boan J, Martinez-Cuesta A, Benito A, Rodriguez J, Panizo A, Gil B, Inarrairaegui M, Herrero I, Quiroga J, Prieto J: Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2006;66:792-800.
23. Lencioni R: Chemoembolization for hepatocellular carcinoma. Semin Oncol 2012;39:503-509.
24. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Hussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, SHARP Investigators Study Group: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
25. http://www.goodrx.com/nexavar?gclid=CK-P2Nbj87oCFct9OgodCXQAaw (accessed May, 6, 2014).
26. Tiong L, Maddern GJ: Systematic review and meta-analysis of survival and disease recurrence after radiofrequency ablation for hepatocellular carcinoma. Br J Surg 2011;98:1210-1224.
27. El-Serag HB, Siegel AB, Davila JA, Shaib YH, Cayton-Woody M, McBride R, McGlynn KA: Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study. J Hepatol 2006;44:158-166.
28. Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA, editors.: SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975-2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014. (accessed May 6, 2014).
29. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA, editors.: SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations), National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975-2009-pops09/, based on November 2011 SEER data submission, posted to the SEER web site, April 2012. (accessed May 6, 2014).
30. Ulahannan SV, Duffy AG, McNeel TS, Kish JK, Dickie LA, Rahma OE, McGlynn KA, Greten TF, Altekruse SF: Earlier presentation and application of curative treatments in hepatocellular carcinoma. Hepatology 2014; [Epub ahead of print].
31. Sherman M: Hepatocellular carcinoma: screening and staging. Clin Liver Dis 2011;15:323-334, vii-x.
32. U.S. Preventive Services Task Force: Hepatitis C Screening. http://www.uspreventiveservicestaskforce. org/uspstf/uspshepc.htm accessed 7/21/2014.
33. Dohmen K, Shirahama M, Shigematsu H, Irie K, Ishibashi H: Optimal treatment strategy for elderly patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2004;19:859-865.
34. Wu Y, Johnson KB, Roccaro G, Lopez J, Zheng H, Muiru A, Ufere N, Rajbhandari R, Kattan O, Chung RT: Poor adherence to AASLD guidelines for chronic hepatitis B management and treatment in a large academic medical center. Am J Gastroenterol 2014;109:867-875.